

James W Janetka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7127724/publications.pdf>

Version: 2024-02-01

65
papers

3,772
citations

136885

32
h-index

128225

60
g-index

85
all docs

85
docs citations

85
times ranked

5115
citing authors

#	ARTICLE	IF	CITATIONS
1	AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2955-2966.	1.9	364
2	Treatment and Prevention of Urinary Tract Infection with Orally Active FimH Inhibitors. <i>Science Translational Medicine</i> , 2011, 3, 109ra115.	5.8	254
3	Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. <i>Trends in Molecular Medicine</i> , 2011, 17, 88-96.	3.5	240
4	Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist. <i>Nature</i> , 2017, 546, 528-532.	13.7	231
5	Structure-Based Drug Design and Optimization of Mannoside Bacterial FimH Antagonists. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 4779-4792.	2.9	220
6	MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A. <i>Science</i> , 2018, 360, 336-341.	6.0	187
7	Structure-Guided Design of Potent and Selective Pyrimidylpyrrole Inhibitors of Extracellular Signal-Regulated Kinase (ERK) Using Conformational Control. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 6362-6368.	2.9	133
8	A FimH Inhibitor Prevents Acute Bladder Infection and Treats Chronic Cystitis Caused by Multidrug-Resistant Uropathogenic Escherichia coli ST131. <i>Journal of Infectious Diseases</i> , 2013, 208, 921-928.	1.9	116
9	Lead Optimization Studies on FimH Antagonists: Discovery of Potent and Orally Bioavailable Ortho-Substituted Biphenyl Mannosides. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 3945-3959.	2.9	112
10	Flipped Out: Structure-Guided Design of Selective Pyrazolylpyrrole ERK Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 1280-1287.	2.9	108
11	Combinatorial Small-Molecule Therapy Prevents Uropathogenic Escherichia coli Catheter-Associated Urinary Tract Infections in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4738-4745.	1.4	94
12	Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment. <i>Cancers</i> , 2017, 9, 35.	1.7	85
13	Antivirulence C-Mannosides as Antibiotic-Sparing, Oral Therapeutics for Urinary Tract Infections. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 9390-9408.	2.9	84
14	Total Synthesis of the Cyclic Biphenyl Ether Peptides K-13 and OF4949-III via SNAr Macrocyclization of Peptidyl Ruthenium π -Arene Complexes. <i>Journal of the American Chemical Society</i> , 1997, 119, 6488-6495.	6.6	83
15	Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 711-731.	2.5	71
16	Precision antimicrobial therapeutics: the path of least resistance?. <i>Npj Biofilms and Microbiomes</i> , 2018, 4, 4.	2.9	69
17	Synthesis of peptidyl ruthenium π -arene complexes: application to the synthesis of cyclic biphenyl ether peptides. <i>Journal of the American Chemical Society</i> , 1995, 117, 10585-10586.	6.6	66
18	Structure-based discovery of glycomimetic FimH ligands as inhibitors of bacterial adhesion during urinary tract infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E2819-E2828.	3.3	63

#	ARTICLE	IF	CITATIONS
19	Keeping checkpoint kinases in line: new selective inhibitors in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1331-1340.	1.9	62
20	Novel Cyclic Biphenyl Ether Peptide β^2 -Strand Mimetics and HIV-Protease Inhibitors. <i>Journal of the American Chemical Society</i> , 1997, 119, 441-442.	6.6	59
21	Discovery of Checkpoint Kinase Inhibitor (<i>S</i>)-5-(3-Fluorophenyl)- <i>N</i> -(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by Structure-Based Design and Optimization of Thiophenecarboxamide Ureas. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 5130-5142.	2.9	58
22	Human Urine Decreases Function and Expression of Type 1 Pili in Uropathogenic <i>Escherichia coli</i> . <i>MBio</i> , 2015, 6, e00820.	1.8	58
23	Inhibition of Calcium Dependent Protein Kinase 1 (CDPK1) by Pyrazolopyrimidine Analogs Decreases Establishment and Reoccurrence of Central Nervous System Disease by <i>Toxoplasma gondii</i> . <i>Journal of Medicinal Chemistry</i> , 2017, 60, 9976-9989.	2.9	57
24	Photoaffinity labeling with cholesterol analogues precisely maps a cholesterol-binding site in voltage-dependent anion channel-1. <i>Journal of Biological Chemistry</i> , 2017, 292, 9294-9304.	1.6	54
25	A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	54
26	Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI. <i>ChemMedChem</i> , 2016, 11, 367-373.	1.6	53
27	Evolutionary fine-tuning of conformational ensembles in FimH during host-pathogen interactions. <i>Science Advances</i> , 2017, 3, e1601944.	4.7	50
28	L-Selectride as a General Reagent for the O-Demethylation and N-Decarbomethoxylation of Opium Alkaloids and Derivatives1. <i>Journal of Organic Chemistry</i> , 1998, 63, 4392-4396.	1.7	47
29	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease. <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 175-197.	2.4	47
30	Inhibitors of HGFA, Matrilysin, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 1219-1224.	1.3	41
31	Checkpoint kinase inhibitors: a review of the patent literature. <i>Expert Opinion on Therapeutic Patents</i> , 2009, 19, 165-197.	2.4	38
32	Distinguishing the Contribution of Type 1 Pili from That of Other QseB-Misregulated Factors when QseC Is Absent during Urinary Tract Infection. <i>Infection and Immunity</i> , 2012, 80, 2826-2834.	1.0	35
33	β -Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer. <i>ChemMedChem</i> , 2016, 11, 585-599.	1.6	32
34	Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4242-4248.	1.0	31
35	Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 2328-2343.	1.4	31
36	Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation. <i>Oncotarget</i> , 2017, 8, 63014-63025.	0.8	27

#	ARTICLE	IF	CITATIONS
37	Identification of small molecule enzyme inhibitors as broad-spectrum anthelmintics. <i>Scientific Reports</i> , 2019, 9, 9085.	1.6	25
38	Inhibitors of checkpoint kinases: from discovery to the clinic. <i>Current Opinion in Drug Discovery & Development</i> , 2007, 10, 473-86.	1.9	23
39	Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 480-490.	2.9	22
40	Hepatocyte growth factor activator inhibitor-2 stabilizes Epcam and maintains epithelial organization in the mouse intestine. <i>Communications Biology</i> , 2019, 2, 11.	2.0	21
41	Discovery of novel hedgehog antagonists from cell-based screening: Isosteric modification of p38 bisamides as potent inhibitors of SMO. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 4907-4911.	1.0	20
42	Identification of Small Molecule Inhibitors That Block the <i>Toxoplasma gondii</i> Rhopty Kinase ROP18. <i>ACS Infectious Diseases</i> , 2016, 2, 194-206.	1.8	20
43	Click Chemistry Reagent for Identification of Sites of Covalent Ligand Incorporation in Integral Membrane Proteins. <i>Analytical Chemistry</i> , 2017, 89, 2636-2644.	3.2	20
44	Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 1061-1073.	2.9	19
45	A host receptor enables type 1 pilus-mediated pathogenesis of <i>Escherichia coli</i> pyelonephritis. <i>PLoS Pathogens</i> , 2021, 17, e1009314.	2.1	19
46	Small Molecule Inhibitors of Metabolic Enzymes Repurposed as a New Class of Anthelmintics. <i>ACS Infectious Diseases</i> , 2018, 4, 1130-1145.	1.8	18
47	Biphenyl Gal and GalNAc FmlH Lectin Antagonists of Uropathogenic <i>E. coli</i> (UPEC): Optimization through Iterative Rational Drug Design. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 467-479.	2.9	18
48	An Integrated Approach to Identify New Anti-Filarial Leads to Treat River Blindness, a Neglected Tropical Disease. <i>Pathogens</i> , 2021, 10, 71.	1.2	16
49	Discovery of a novel class of triazolones as Checkpoint Kinase inhibitors—Hit to lead exploration. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 5133-5138.	1.0	14
50	Recent progress on inhibitors of the type II transmembrane serine proteases, hepsin, matriptase and matriptase-2. <i>Future Medicinal Chemistry</i> , 2019, 11, 743-769.	1.1	14
51	Optimizing Pyrazolopyrimidine Inhibitors of Calcium Dependent Protein Kinase 1 for Treatment of Acute and Chronic Toxoplasmosis. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 6144-6163.	2.9	14
52	A Cyclic Side-Chain-Linked Biphenyl Ether Tripeptide: H ₃ N ⁺ -cyclo-[Phe(4 ^{''} O)-Phe-Phe(3 ^{''} O)]-OMe.Cl ⁺ . <i>Acta Crystallographica Section C: Crystal Structure Communications</i> , 1996, 52, 3112-3114.	0.4	12
53	Enantioconvergent Synthesis of (S ^{''})-(2R,5S)-1-Allyl-2,5-dimethylpiperazine, an Intermediate to μ -Opioid Receptor Ligands. <i>Journal of Organic Chemistry</i> , 2003, 68, 3976-3980.	1.7	8
54	Piperidine carbamate peptidomimetic inhibitors of the serine proteases HGFA, matriptase and hepsin. <i>MedChemComm</i> , 2019, 10, 1646-1655.	3.5	8

#	ARTICLE	IF	CITATIONS
55	Macrocyclic Inhibitors of HGF-Activating Serine Proteases Overcome Resistance to Receptor Tyrosine Kinase Inhibitors and Block Lung Cancer Progression. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 18158-18174.	2.9	8
56	Characterization of parasite-specific indels and their proposed relevance for selective anthelmintic drug targeting. <i>Infection, Genetics and Evolution</i> , 2016, 39, 201-211.	1.0	7
57	Diaryldimethylpiperazine ligands with μ - and δ -opioid receptor affinity: Synthesis of (+)-4-[(1 \pm R)-1-(4-allyl-(2S,5S)-dimethylpiperazin-1-yl)-(3-hydroxyphenyl)methyl]-N-ethyl-N-phenylbenzamide <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 4761-4768.	1.4	5
58	Novel approaches to glycomimetic design: development of small molecular weight lectin antagonists. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 513-536.	2.5	5
59	Aspartyl Protease Inhibitors as Anti-Filarial Drugs. <i>Pathogens</i> , 2022, 11, 707.	1.2	4
60	C α -Glycosides, Array-based Addressable Libraries, and the Versatility of Constant Current Electrochemistry. <i>Electroanalysis</i> , 2016, 28, 2808-2817.	1.5	3
61	Abstract 3451: Non-genetic RTK-mediated cetuximab resistance in colorectal cancer offers multiple targets for therapeutic intervention. , 2020, , .		3
62	DDIS-10. TARGETING HGF/MET IN GBM BY RESTORING SPINT2 FUNCTION. <i>Neuro-Oncology</i> , 2016, 18, vi49-vi49.	0.6	0
63	Heteroarylamide smoothed inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2-pyridylmethoxy)benzamide (AZD7254). <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115227.	1.4	0
64	Abstract LB-197: Hepatocyte Growth Factor Activator (HGFA) Inhibitors of c-MET/RON Kinase Signaling. , 2011, , .		0
65	Abstract 2523: Mechanism-based inhibitors of HGFA, matriptase and hepsin for breast cancer treatment. , 2014, , .		0